QSP models of NASH should include equations that describe these pathophysiologic mechanisms in addition to the primary biomarkers (e.g., plasma ALT) and histologic outputs that are used to determine efficacy. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.